Meeting NewsVideo

VIDEO: Uncertain role for dacomitinib in current lung cancer landscape

CHICAGO — Dacomitinib improved OS compared with gefitinib among patients with newly diagnosed, advanced EGFR-positive non-small cell lung cancer, according to updated phase 3 study results from the ARCHER 1050 trial presented at the ASCO Annual Meeting.

Final results showed patients treated with dacomitinib (PF-00299804, Pfizer) had an improvement of 5.5 months in median PFS and 7.3 months for median OS.

“This clearly puts another important EGFR inhibitor in the front-line space for non-small cell lung cancer patients,” Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, told HemOnc Today.

However, as Ramalingam said, median PFS in previous studies with dacomitinib is 14.5 months and is shorter in duration than the median PFS of 19 months found in osimertinib (Tagrisso, AstraZeneca).

Additionally, the adverse event profile for dacomitinb is slightly more severe compared with first-generation EGFR inhibitors, and third-generation osimertinib, according to Ramalingam.

“For these reasons, from my personal standpoint, it is not clear to me how dacomitinib is going to fit in the current landscape where we already have osimertinib approved by the FDA for front-line use,” he said.

CHICAGO — Dacomitinib improved OS compared with gefitinib among patients with newly diagnosed, advanced EGFR-positive non-small cell lung cancer, according to updated phase 3 study results from the ARCHER 1050 trial presented at the ASCO Annual Meeting.

Final results showed patients treated with dacomitinib (PF-00299804, Pfizer) had an improvement of 5.5 months in median PFS and 7.3 months for median OS.

“This clearly puts another important EGFR inhibitor in the front-line space for non-small cell lung cancer patients,” Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, told HemOnc Today.

However, as Ramalingam said, median PFS in previous studies with dacomitinib is 14.5 months and is shorter in duration than the median PFS of 19 months found in osimertinib (Tagrisso, AstraZeneca).

Additionally, the adverse event profile for dacomitinb is slightly more severe compared with first-generation EGFR inhibitors, and third-generation osimertinib, according to Ramalingam.

“For these reasons, from my personal standpoint, it is not clear to me how dacomitinib is going to fit in the current landscape where we already have osimertinib approved by the FDA for front-line use,” he said.

    See more from Discoveries from ASCO: Lung Cancer

    Healio Jobs